Media Mentions

Cancer Research UK recently highlighted the Ivy Brain Tumor Center for its groundbreaking work in glioblastoma research. Led by Dr. Nader Sanai, whose personal connection to the disease drives his passion, the Ivy Center is at the forefront of developing innovative treatments for brain cancer. With a focus on overcoming challenges such as limited drug development and complex tumor biology, the Ivy Center is committed to advancing therapies that can improve the lives of patients with glioblastoma.

Dr. Shewetal Mehta, PhD, Deputy Director at the Ivy Brain Tumor Center, discusses cutting-edge brain cancer research with CancerNetwork®. She shares insights on early-phase clinical trials, including a phase 0/1 trial for BDTX-1535, an EGFR inhibitor for high-grade glioma, and the importance of biomarker testing in personalizing treatment. Dr. Mehta also explores the potential of new therapies like proteolysis targeting chimeras and antibody-drug conjugates. Explore more by watching her mini-episodes now.

Dr. Nader Sanai, Director of the Ivy Brain Tumor Center, was featured on the WeTrials Podcast, where he discussed groundbreaking advancements in brain tumor research and clinical trials. In the episode, Dr. Sanai highlights the role of early-phase clinical trials in developing new treatments, including the promising potential of Niraparib, a drug moving from trials to global studies. He also explores how genomic data is revolutionizing personalized medicine for brain tumor patients, offering hope for better outcomes. Tune in to hear Dr. Sanai’s insights on the future of brain tumor care and the innovative work being done at the Ivy Brain Tumor Center. Watch now!

Arizona Family recently featured the Ivy Brain Tumor Center and Dr. Nader Sanai, who highlighted the seriousness of glioblastoma (GBM). Lanette Veres, a brain tumor survivor diagnosed with a grade 3 glioma in 1998, shared her inspiring journey of resilience after losing her grandmother to GBM. Veres founded the Gray Matters Foundation in 2007 to support brain cancer patients and remains hopeful about new treatments, stating, “Hope never grows old.” Our Phase 3 Gliofocus Study testing the drug Niraparib, has shown promising results in early trials. Watch now!

FOX 10 Phoenix recently featured a segment on the Ivy Brain Tumor Center, highlighting the journey of patient Katie Reed and insights from Deputy Director, Shwetal Mehta, PhD. The discussion focused on the challenges of glioblastoma, an aggressive brain cancer, and the urgent need for new treatments and a cure. This segment underscores the critical work being done to advance research and provide hope to patients facing this daunting diagnosis. Watch now!

BrainWise recently featured the Ivy Brain Tumor Center in the article "Understanding Brain Tumors," where Dr. Yoshie Umemura, Chief of Neuro-Oncology at Barrow Neurological Institute and Chief Medical Officer at the Ivy Center, discusses the differences between primary and secondary brain tumors. Read more!

Clinical Trials Arena spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute, which has begun the Phase III Gliofocus trial of niraparib for recently diagnosed MGMT-unmethylated glioblastoma. Supported by GSK, the trial will involve 450 subjects across over 100 sites in 11 countries. Positive data from earlier trials led to this advancement. The study will compare niraparib’s efficacy to the standard chemotherapy, temozolomide. Dr. Nader Sanai, Director of the Ivy Center, highlighted the trial's potential to improve glioblastoma treatment outcomes.

Channel 12News recently featured Marie Donahue, a dedicated U.S. Navy member and patient at the Ivy Brain Tumor Center, in honor of Brain Tumor Awareness Month. Despite facing a daunting brain tumor diagnosis, Marie has tackled every day with an adventurous spirit and a renewed outlook on life. Watch her inspiring story now!

Endpoints News featured The Ivy Brain Tumor Center’s Phase 0/2 study of niraparib, GSK’s PARP inhibitor, in newly diagnosed glioblastoma patients. This study had promising results and has led the Ivy Brain Tumor Center and GSK to collaborate on a Phase 3 study of niraparib versus temozolomide in MGMT-unmethylated glioblastoma. Read more!

Good Morning Arizona spotlighted the Ivy Brain Tumor Center at Barrow Neurological Institute in recognition of Brain Tumor Awareness Month. As part of this initiative, Cold Beer and Cheeseburgers has teamed up with the Ivy Center for their annual Dine & Donate campaign. This partnership plays a crucial role in advancing vital research efforts aimed at combating brain tumors. Learn more about how you can support this important cause.